RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.

Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to "tangible signs of a more constructive spending environmen

Diagnostics surged 11% organically as AI-driven demand accelerated.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows

Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...

Moby summary of Revvity, Inc.'s Q2 2026 earnings call

Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.

Revvity Inc (RVTY) beats expectations with 3% organic growth, raises full-year outlook on robust diagnostics performance and AI-driven demand.

Revvity, Inc. (NYSE:RVTY) reported second-quarter 2026 results that exceeded Wall Street expectations, prompting the health sciences company to raise its guidance for the full year.

Revvity (RVTY) delivered earnings and revenue surprises of +14.63% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Life sciences company Revvity (NYSE:RVTY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.2% year on year to $729.7 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.41 per share was 15.9% above analysts’ consensus estimates.

Life sciences company Revvity (NYSE:RVTY) will be reporting earnings this Tuesday before the bell. Here’s what investors should know.

Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.

RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?

CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.

RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.

If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.